Mesavancol

Mesalazine, the active ingredient in Mesavancol, is a 5‑aminosalicylic acid (5‑ASA) presented as an oral formulation for oral use. It is employed to reduce intestinal inflammation in patients with ulcerative colitis and Crohn’s disease, targeting the gastrointestinal mucosa and is classified as an anti‑inflammatory agent.

GNH USA supplies Mesavancol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Mesavancol is a 5‑ASA drug that acts locally in the gut to control inflammatory bowel disease.

- Ulcerative colitis: induces remission and maintains disease control by reducing mucosal inflammation. - Crohn's disease: alleviates intestinal inflammation in colonic involvement, supporting symptom relief. - Maintenance therapy: helps prevent relapse after induction of remission in chronic inflammatory bowel conditions.

Mesavancol may be associated with a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Abdominal pain: cramping or discomfort in the lower abdomen. - Headache: transient tension‑type headache. - Flatulence: increased intestinal gas. - Rash: mild skin erythema or itching. - Diarrhoea: loose stools occasionally.

Serious or Rare Side Effects: - Myocarditis: inflammation of heart muscle, requiring immediate medical attention. - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe allergic reactions: anaphylaxis, angioedema, or urticaria. - Blood dyscrasias: agranulocytosis or aplastic anaemia. - Hepatic dysfunction: jaundice or elevated liver enzymes. - Renal impairment: acute interstitial nephritis or reduced kidney function.

Before initiating Mesavancol, clinicians should consider several safety measures.

- Renal function monitoring: assess serum creatinine and eGFR regularly. - Hepatic function monitoring: check liver enzymes periodically. - Disease activity assessment: ensure active disease is documented before therapy. - Hypersensitivity screening: avoid in patients with known allergy to mesalazine or related compounds. - Pregnancy considerations: use only if potential benefit justifies potential risk, as safety data are limited. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Mesavancol can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Azathioprine: heightened risk of bone marrow suppression. - Cyclosporine: potential nephrotoxicity augmentation. - Live vaccines: may reduce vaccine efficacy or increase infection risk.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): additive renal toxicity. - Diuretics: possible electrolyte disturbances. - Corticosteroids: may enhance gastrointestinal side effects. - Oral contraceptives: potential reduction in contraceptive effectiveness.